Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab in Viral ARDS (SILVAR)
NCT04616586Phase 3Terminated
- Sponsor
- Recordati SpA
- Start
- Nov 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of siltuximab in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by Recordati SpA. Started Nov 2020; status: terminated.
02
Drugs
siltuximab
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04616586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616586.